LifeStance Health Group (LFST) News Today

LifeStance Health Group, Inc. (NASDAQ: LFST) shares have increased as investors respond to a strong second-quarter report, raised full-year outlook, and a bullish analyst upgrade.

• Positive Sentiment: Q2 earnings beat expectations: LifeStance reported adjusted earnings of $0.06 per share, versus the $0.03 consensus estimate, compared with a $0.01 loss in the year-ago quarter. Revenue rose 26.1% year over year to approximately $435.4 million, exceeding expectations of $414.6 million. LifeStance Health Group Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved sharply: Net income reached $23.6 million, versus a $3.8 million net loss last year, while adjusted EBITDA nearly doubled to $66.0 million. Visit volume increased 19% to 2.6 million, and the clinician base grew 11% to 8,542, supporting continued operating leverage. LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
• Positive Sentiment: 2026 outlook raised: Management increased full-year revenue guidance to $1.685 billion-$1.725 billion and adjusted EBITDA guidance to $215 million-$235 million. Third-quarter revenue guidance of $420 million-$440 million is also above the roughly $417.7 million consensus estimate.
• Positive Sentiment: Share repurchase authorization: The board approved a new program allowing up to $100 million in common-stock repurchases, potentially providing additional support for earnings per share and the stock price.
• Positive Sentiment: Analyst confidence increased: BTIG Research raised its price target from $15 to $16 and reaffirmed a “buy” rating, implying substantial upside from recent trading levels. BTIG Research Price Target Update
• Neutral Sentiment: Balance-sheet considerations: LifeStance generated $99.9 million of operating cash flow in Q2 and ended the period with $225.9 million in cash, compared with $259.0 million in net long-term debt.
• Negative Sentiment: Insider selling remains a risk: Recent reporting indicates no insider purchases and substantial insider sales over the past six months, which could temper investor enthusiasm despite the strong operating results.